Allworth Financial LP Boosts Stock Position in Bristol Myers Squibb Company $BMY

Allworth Financial LP boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 37.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 111,801 shares of the biopharmaceutical company’s stock after purchasing an additional 30,415 shares during the quarter. Allworth Financial LP’s holdings in Bristol Myers Squibb were worth $5,175,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Trifecta Capital Advisors LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth about $25,000. REAP Financial Group LLC lifted its holdings in shares of Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 428 shares during the last quarter. Accent Capital Management LLC purchased a new position in Bristol Myers Squibb in the first quarter worth about $33,000. CBIZ Investment Advisory Services LLC increased its stake in Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 231 shares during the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new stake in Bristol Myers Squibb during the first quarter valued at approximately $36,000. Institutional investors own 76.41% of the company’s stock.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is currently owned by company insiders.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $48.70 on Wednesday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market capitalization of $99.14 billion, a PE ratio of 19.64, a P/E/G ratio of 2.23 and a beta of 0.33. The company has a 50 day moving average price of $45.28 and a 200-day moving average price of $46.68. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s quarterly revenue was up 2.8% on a year-over-year basis. During the same period last year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.1%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s payout ratio is presently 83.78%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Four investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $55.45.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.